84 related articles for article (PubMed ID: 26458315)
1. FBXL10 contributes to the progression of nasopharyngeal carcinoma via involving in PI3K/mTOR pathway.
Ren Y; Wu L; Li X; Li W; Yang Y; Zhang M
Neoplasma; 2015; 62(6):925-31. PubMed ID: 26458315
[TBL] [Abstract][Full Text] [Related]
2. The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway.
Luo H; Yu YY; Chen HM; Wu W; Li Y; Lin H
Exp Ther Med; 2019 Jan; 17(1):99-106. PubMed ID: 30651769
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylethanolamine-binding protein 4 promotes lung cancer cells proliferation and invasion via PI3K/Akt/mTOR axis.
Yu G; Huang B; Chen G; Mi Y
J Thorac Dis; 2015 Oct; 7(10):1806-16. PubMed ID: 26623104
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
5. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
[TBL] [Abstract][Full Text] [Related]
6. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
8. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway.
Feng G; Arima Y; Midorikawa K; Kobayashi H; Oikawa S; Zhao W; Zhang Z; Takeuchi K; Murata M
Cancer Cell Int; 2023 Aug; 23(1):185. PubMed ID: 37644594
[TBL] [Abstract][Full Text] [Related]
10. Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells.
Yu Y; Yu X; Ma J; Tong Y; Yao J
Int J Oncol; 2016 Jul; 49(1):285-93. PubMed ID: 27176231
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer.
Yang F; Gao JY; Chen H; Du ZH; Zhang XQ; Gao W
Onco Targets Ther; 2017; 10():4413-4422. PubMed ID: 28979133
[TBL] [Abstract][Full Text] [Related]
12. BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway.
Liu X; Xie C; Li A; Zhang Y; Liu X; Zhou S; Shen J; Huo Z; Cao W; Ma Y; Xu R; Xing Y; Xie Y; Cai S; Tang X
Am J Transl Res; 2019; 11(12):7255-7271. PubMed ID: 31934276
[TBL] [Abstract][Full Text] [Related]
13. PNCK depletion inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells
Xu Y; Wang J; Cai S; Chen G; Xiao N; Fu Y; Chen Q; Qiu S
J Cancer; 2019; 10(27):6925-6932. PubMed ID: 31839828
[No Abstract] [Full Text] [Related]
14. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
15. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
17. ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma.
Chen Q; Zheng W; Zhu L; Yao D; Wang C; Song Y; Hu S; Liu H; Bai Y; Pan Y; Zhang J; Guan J; Shao C
Front Cell Dev Biol; 2020; 8():232. PubMed ID: 32373608
[TBL] [Abstract][Full Text] [Related]
18. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
19. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; Corchete LA; San Miguel JF; Del Cañizo C; Blanco B
J Hematol Oncol; 2016 Oct; 9(1):113. PubMed ID: 27765055
[TBL] [Abstract][Full Text] [Related]
20. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
Zhu W; Fu W; Hu L
Cancer Biother Radiopharm; 2013 Nov; 28(9):665-73. PubMed ID: 23768063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
